2026 Q1 -tulosraportti
92 päivää sitten
‧28 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenThe Price-Action the case is undergoing RIGHT NOW is very typical and quite predictable - for a case where market consensus is generally positive. This can all be read on the naked chart. Zoom out on a weekly chart, (i.e., a chart where one candle represents one week's price-action) and you will immediately notice - that the case has been running a Trading-Range since end-February 2020 and up until today. For six years there has been no value increase in the case, and it has merely wobbled around between a ceiling around 7.6ish and a floor around 3.8ish. (Do not take these values literally, it's roughly just the area it has generally been operating in.) What can be read from the chart from 2012 and up until today - in the very big picture - is the classic capital allocation in the case, which is continuously tested in a downward direction as the reality of the case unfolds. "It is extremely difficult to develop a company to success, and in most cases it takes much longer than the patience the markets are willing to invest." Fast Forward to today: After now having run a Trading-Range for six years, the case has reached a point that could become a bit of a Make or Break for the company. Their NDA which FDA approved as of March 27-26 and which many are awaiting a decision on by end-September will be crucial for the company's future. If this is held up against the ongoing Price-Action RIGHT NOW, it is clear to see - and completely expected! - that the six-year Trading-Range is not being broken up RIGHT NOW, the uncertainty surrounding FDA's decision is too great for this, although everyone expects their decision to be positive. This situation can be actively used by the attentive trader, in the ambition to constantly allocate their working capital to Minimum Risk - and what you see RIGHT NOW is a market that is probably positioning itself in the case, but at the same time attempting to position itself for Minimum Risk.. The double-top, (1st top = May 19 / 2nd top = July 24) formation I have written about in the thread right below here is a crystal clear example of such positioning. The market did not break the latest top, (because then it would have broken the six-year Trading-Range!) and will therefore consolidate until FDA's decision. And where is that then? How on earth could anyone, myself included, speak with absolute certainty about it! The magic crystal balls that see into the future do not exist! But what one can do is to decide for oneself whether the rejected Trading-Range top means - that Price-Action is now on its way back towards the bottom of the Trading-Range, (just as the case has now been running for six years!) I have already written in the thread below where I believe Price-Action is taking the case RIGHT NOW towards the FDA end-September decision, and so far it looks like I will be proven right. Disclaimer: I am mega positive on this company provided that the upcoming FDA announcement is positive, it will be a Game-Changer for the company. Until that point, it simply continues to apply as an investor, to allocate one's working capital to Minimum Risk. Ladies & Gentlemen☝️☝️ Bet's please☝️☝️
Don't forget the 10 largest shareholders account for over 60 %. E.g., Frazier Lifescience now for 16 % after the last emission. They don't mess around with business. I follow that strategy so far and also take the opportunity to top up. Name Capital Votes EGTX EGTX C Verified Frazier Life Sciences 16,66% 16,66% 77 437 961 2026-05-29 Cidro Förvaltning AB 10,09% 10,09% 46 900 000 2026-06-26 Fjärde AP-fonden 6,86% 6,86% 31 883 446 2026-06-26 Cetoros AB (Peder Walberg) 6,19% 6,19% 28 776 221 2026-06-26 The Invus Group 4,68% 4,71% 21 911 823 2026-05-27 Linc AB 3,85% 3,85% 17 917 860 2026-06-26 Avla Holding AB (Kennet Rooth) 3,80% 3,80% 17 668 330 2026-06-26 Feoh Investments UK LLP 3,47% 3,49% 16 249 434 2026-05-27 Woodline Partners LP 2,42% 2,43% 11 325 960 2026-05-27 Avanza Pension 2,38% 2,38% 11 047 464 2026-06-26 Totalt 10 60,40% 60,46% 281 118 499
·2 päivää sittenSweden's best case right now considering R/R and potential. Alone on the market, full cash before launch, approved in EU, patent until 2045, possible USA approval soon and voucher worth 1 billion🤑 Ö Several factors speak for an FDA approval of Egetis Therapeutics' drug Emcitate® (tiratricol) for the treatment of MCT8 deficiency. The most crucial factor is that the drug has been granted Priority Review with a PDUFA target date (decision date) set for September 28, 2026. Here are the main reasons why the approval assessment looks strong:Existing approval in EU: Emcitate is already approved and has been launched in Europe, which means that extensive clinical safety and efficacy data has already been validated by European drug authorities. [No planned expert meetings: Upon acceptance of the application, FDA announced that the agency currently does not plan to hold any advisory committee meeting (Advisory Committee). This is often interpreted positively, as it indicates that FDA sees no significant controversies or question marks regarding safety and efficacy. Regulatory status: The drug has previously been granted Breakthrough Therapy Designation and Fast Track Designation, which underscores how urgent it is for a patient group that currently lacks approved treatment options in the USA. Extensive data: The American application (NDA) is based on solid documentation from several studies (including Triac Trial I, Triac Trial II and ReTRIACt) as well as data from an American Expanded Access Program (EAP).Conditionally approved drug name: In April 2026, FDA announced that the proposed drug name Emcitate is conditionally acceptable, which is an administrative milestone reached in the final phase of an approval process. Also consider that they are alone on the market, receive a voucher worth 1 billion, and have strong owners. I believe in a Hole in one@hajaa: I know the company, have studied it thoroughly. And yes, it looks really attractive. The market has now for a long time 'kept the company at arm's length' awaiting what happens next - and the market is always right. Ladies & Gentlemen☝️☝️ Bet’s please☝️☝️ Closing prices above 6.7ish, alternatively around price 6 - 5.8ish are the primary entries in the ongoing price-action - until they occur, one should just sit on one's hands.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
92 päivää sitten
‧28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenThe Price-Action the case is undergoing RIGHT NOW is very typical and quite predictable - for a case where market consensus is generally positive. This can all be read on the naked chart. Zoom out on a weekly chart, (i.e., a chart where one candle represents one week's price-action) and you will immediately notice - that the case has been running a Trading-Range since end-February 2020 and up until today. For six years there has been no value increase in the case, and it has merely wobbled around between a ceiling around 7.6ish and a floor around 3.8ish. (Do not take these values literally, it's roughly just the area it has generally been operating in.) What can be read from the chart from 2012 and up until today - in the very big picture - is the classic capital allocation in the case, which is continuously tested in a downward direction as the reality of the case unfolds. "It is extremely difficult to develop a company to success, and in most cases it takes much longer than the patience the markets are willing to invest." Fast Forward to today: After now having run a Trading-Range for six years, the case has reached a point that could become a bit of a Make or Break for the company. Their NDA which FDA approved as of March 27-26 and which many are awaiting a decision on by end-September will be crucial for the company's future. If this is held up against the ongoing Price-Action RIGHT NOW, it is clear to see - and completely expected! - that the six-year Trading-Range is not being broken up RIGHT NOW, the uncertainty surrounding FDA's decision is too great for this, although everyone expects their decision to be positive. This situation can be actively used by the attentive trader, in the ambition to constantly allocate their working capital to Minimum Risk - and what you see RIGHT NOW is a market that is probably positioning itself in the case, but at the same time attempting to position itself for Minimum Risk.. The double-top, (1st top = May 19 / 2nd top = July 24) formation I have written about in the thread right below here is a crystal clear example of such positioning. The market did not break the latest top, (because then it would have broken the six-year Trading-Range!) and will therefore consolidate until FDA's decision. And where is that then? How on earth could anyone, myself included, speak with absolute certainty about it! The magic crystal balls that see into the future do not exist! But what one can do is to decide for oneself whether the rejected Trading-Range top means - that Price-Action is now on its way back towards the bottom of the Trading-Range, (just as the case has now been running for six years!) I have already written in the thread below where I believe Price-Action is taking the case RIGHT NOW towards the FDA end-September decision, and so far it looks like I will be proven right. Disclaimer: I am mega positive on this company provided that the upcoming FDA announcement is positive, it will be a Game-Changer for the company. Until that point, it simply continues to apply as an investor, to allocate one's working capital to Minimum Risk. Ladies & Gentlemen☝️☝️ Bet's please☝️☝️Don't forget the 10 largest shareholders account for over 60 %. E.g., Frazier Lifescience now for 16 % after the last emission. They don't mess around with business. I follow that strategy so far and also take the opportunity to top up. Name Capital Votes EGTX EGTX C Verified Frazier Life Sciences 16,66% 16,66% 77 437 961 2026-05-29 Cidro Förvaltning AB 10,09% 10,09% 46 900 000 2026-06-26 Fjärde AP-fonden 6,86% 6,86% 31 883 446 2026-06-26 Cetoros AB (Peder Walberg) 6,19% 6,19% 28 776 221 2026-06-26 The Invus Group 4,68% 4,71% 21 911 823 2026-05-27 Linc AB 3,85% 3,85% 17 917 860 2026-06-26 Avla Holding AB (Kennet Rooth) 3,80% 3,80% 17 668 330 2026-06-26 Feoh Investments UK LLP 3,47% 3,49% 16 249 434 2026-05-27 Woodline Partners LP 2,42% 2,43% 11 325 960 2026-05-27 Avanza Pension 2,38% 2,38% 11 047 464 2026-06-26 Totalt 10 60,40% 60,46% 281 118 499
- ·2 päivää sittenSweden's best case right now considering R/R and potential. Alone on the market, full cash before launch, approved in EU, patent until 2045, possible USA approval soon and voucher worth 1 billion🤑 Ö Several factors speak for an FDA approval of Egetis Therapeutics' drug Emcitate® (tiratricol) for the treatment of MCT8 deficiency. The most crucial factor is that the drug has been granted Priority Review with a PDUFA target date (decision date) set for September 28, 2026. Here are the main reasons why the approval assessment looks strong:Existing approval in EU: Emcitate is already approved and has been launched in Europe, which means that extensive clinical safety and efficacy data has already been validated by European drug authorities. [No planned expert meetings: Upon acceptance of the application, FDA announced that the agency currently does not plan to hold any advisory committee meeting (Advisory Committee). This is often interpreted positively, as it indicates that FDA sees no significant controversies or question marks regarding safety and efficacy. Regulatory status: The drug has previously been granted Breakthrough Therapy Designation and Fast Track Designation, which underscores how urgent it is for a patient group that currently lacks approved treatment options in the USA. Extensive data: The American application (NDA) is based on solid documentation from several studies (including Triac Trial I, Triac Trial II and ReTRIACt) as well as data from an American Expanded Access Program (EAP).Conditionally approved drug name: In April 2026, FDA announced that the proposed drug name Emcitate is conditionally acceptable, which is an administrative milestone reached in the final phase of an approval process. Also consider that they are alone on the market, receive a voucher worth 1 billion, and have strong owners. I believe in a Hole in one@hajaa: I know the company, have studied it thoroughly. And yes, it looks really attractive. The market has now for a long time 'kept the company at arm's length' awaiting what happens next - and the market is always right. Ladies & Gentlemen☝️☝️ Bet’s please☝️☝️ Closing prices above 6.7ish, alternatively around price 6 - 5.8ish are the primary entries in the ongoing price-action - until they occur, one should just sit on one's hands.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
2026 Q1 -tulosraportti
92 päivää sitten
‧28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 21.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenThe Price-Action the case is undergoing RIGHT NOW is very typical and quite predictable - for a case where market consensus is generally positive. This can all be read on the naked chart. Zoom out on a weekly chart, (i.e., a chart where one candle represents one week's price-action) and you will immediately notice - that the case has been running a Trading-Range since end-February 2020 and up until today. For six years there has been no value increase in the case, and it has merely wobbled around between a ceiling around 7.6ish and a floor around 3.8ish. (Do not take these values literally, it's roughly just the area it has generally been operating in.) What can be read from the chart from 2012 and up until today - in the very big picture - is the classic capital allocation in the case, which is continuously tested in a downward direction as the reality of the case unfolds. "It is extremely difficult to develop a company to success, and in most cases it takes much longer than the patience the markets are willing to invest." Fast Forward to today: After now having run a Trading-Range for six years, the case has reached a point that could become a bit of a Make or Break for the company. Their NDA which FDA approved as of March 27-26 and which many are awaiting a decision on by end-September will be crucial for the company's future. If this is held up against the ongoing Price-Action RIGHT NOW, it is clear to see - and completely expected! - that the six-year Trading-Range is not being broken up RIGHT NOW, the uncertainty surrounding FDA's decision is too great for this, although everyone expects their decision to be positive. This situation can be actively used by the attentive trader, in the ambition to constantly allocate their working capital to Minimum Risk - and what you see RIGHT NOW is a market that is probably positioning itself in the case, but at the same time attempting to position itself for Minimum Risk.. The double-top, (1st top = May 19 / 2nd top = July 24) formation I have written about in the thread right below here is a crystal clear example of such positioning. The market did not break the latest top, (because then it would have broken the six-year Trading-Range!) and will therefore consolidate until FDA's decision. And where is that then? How on earth could anyone, myself included, speak with absolute certainty about it! The magic crystal balls that see into the future do not exist! But what one can do is to decide for oneself whether the rejected Trading-Range top means - that Price-Action is now on its way back towards the bottom of the Trading-Range, (just as the case has now been running for six years!) I have already written in the thread below where I believe Price-Action is taking the case RIGHT NOW towards the FDA end-September decision, and so far it looks like I will be proven right. Disclaimer: I am mega positive on this company provided that the upcoming FDA announcement is positive, it will be a Game-Changer for the company. Until that point, it simply continues to apply as an investor, to allocate one's working capital to Minimum Risk. Ladies & Gentlemen☝️☝️ Bet's please☝️☝️Don't forget the 10 largest shareholders account for over 60 %. E.g., Frazier Lifescience now for 16 % after the last emission. They don't mess around with business. I follow that strategy so far and also take the opportunity to top up. Name Capital Votes EGTX EGTX C Verified Frazier Life Sciences 16,66% 16,66% 77 437 961 2026-05-29 Cidro Förvaltning AB 10,09% 10,09% 46 900 000 2026-06-26 Fjärde AP-fonden 6,86% 6,86% 31 883 446 2026-06-26 Cetoros AB (Peder Walberg) 6,19% 6,19% 28 776 221 2026-06-26 The Invus Group 4,68% 4,71% 21 911 823 2026-05-27 Linc AB 3,85% 3,85% 17 917 860 2026-06-26 Avla Holding AB (Kennet Rooth) 3,80% 3,80% 17 668 330 2026-06-26 Feoh Investments UK LLP 3,47% 3,49% 16 249 434 2026-05-27 Woodline Partners LP 2,42% 2,43% 11 325 960 2026-05-27 Avanza Pension 2,38% 2,38% 11 047 464 2026-06-26 Totalt 10 60,40% 60,46% 281 118 499
- ·2 päivää sittenSweden's best case right now considering R/R and potential. Alone on the market, full cash before launch, approved in EU, patent until 2045, possible USA approval soon and voucher worth 1 billion🤑 Ö Several factors speak for an FDA approval of Egetis Therapeutics' drug Emcitate® (tiratricol) for the treatment of MCT8 deficiency. The most crucial factor is that the drug has been granted Priority Review with a PDUFA target date (decision date) set for September 28, 2026. Here are the main reasons why the approval assessment looks strong:Existing approval in EU: Emcitate is already approved and has been launched in Europe, which means that extensive clinical safety and efficacy data has already been validated by European drug authorities. [No planned expert meetings: Upon acceptance of the application, FDA announced that the agency currently does not plan to hold any advisory committee meeting (Advisory Committee). This is often interpreted positively, as it indicates that FDA sees no significant controversies or question marks regarding safety and efficacy. Regulatory status: The drug has previously been granted Breakthrough Therapy Designation and Fast Track Designation, which underscores how urgent it is for a patient group that currently lacks approved treatment options in the USA. Extensive data: The American application (NDA) is based on solid documentation from several studies (including Triac Trial I, Triac Trial II and ReTRIACt) as well as data from an American Expanded Access Program (EAP).Conditionally approved drug name: In April 2026, FDA announced that the proposed drug name Emcitate is conditionally acceptable, which is an administrative milestone reached in the final phase of an approval process. Also consider that they are alone on the market, receive a voucher worth 1 billion, and have strong owners. I believe in a Hole in one@hajaa: I know the company, have studied it thoroughly. And yes, it looks really attractive. The market has now for a long time 'kept the company at arm's length' awaiting what happens next - and the market is always right. Ladies & Gentlemen☝️☝️ Bet’s please☝️☝️ Closing prices above 6.7ish, alternatively around price 6 - 5.8ish are the primary entries in the ongoing price-action - until they occur, one should just sit on one's hands.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt